1. Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury
   null Kongpol et al, 2019, Biomolecules CrossRef
2. SLPI - a Biomarker of Acute Kidney Injury after Open and Endovascular Thoracoabdominal Aortic Aneurysm (TAAA) Repair
   Luisa Averdunk et al, 2020, Scientific Reports CrossRef
3. Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury
   Podsawee Mongkolpathumrat et al, 2021, Biomedicines CrossRef
4. Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury
   Podsawee Mongkolpathumrat et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
5. Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
   Podsawee Mongkolpathumrat et al, 2022, Biomedicines CrossRef